Anne McTiernan has provideda comprehensive and balancedreview of a complex topic,namely, “Obesity and Cancer: TheRisks, Science, and Potential ManagementStrategies.” The impressiveweight of assembled evidence from thecited observational studies has been sufficientto influence several cancer organizations,including the AmericanCancer Society and the American Institutefor Cancer Prevention, to issuerecommendations regarding nutritionand physical activity in relationship tocancer.[1,2] However, clinical practiceis unlikely to undergo substantialchange in the absence of prospectivetrials demonstrating benefit on clinicaloutcomes.[3] For at least the breast cancerand obesity question, informationfrom phase III randomized, prospectiveclinical trials evaluating lifestyleintervention influence on clinical outcomeare anticipated in the near future.
Anne McTiernan has provided a comprehensive and balanced review of a complex topic, namely, "Obesity and Cancer: The Risks, Science, and Potential Management Strategies." The impressive weight of assembled evidence from the cited observational studies has been sufficient to influence several cancer organizations, including the American Cancer Society and the American Institute for Cancer Prevention, to issue recommendations regarding nutrition and physical activity in relationship to cancer.[1,2] However, clinical practice is unlikely to undergo substantial change in the absence of prospective trials demonstrating benefit on clinical outcomes.[3] For at least the breast cancer and obesity question, information from phase III randomized, prospective clinical trials evaluating lifestyle intervention influence on clinical outcome are anticipated in the near future. There are currently no full-scale studies evaluating weight loss as related to either breast cancer incidence or recurrence. However, women who are obese are more likely to have higher dietary fat intake and lower physical activity when compared to nonobese women. In addition, in at least some observational reports, all three factors (obesity, higher fat intake, and lower physical activity) have been related to breast cancer outcome.[4-7] There are several randomized clinical trials currently evaluating dietary lifestyle inter- ventions that incorporate fat-intake reduction, and in some cases, other nutrients, to begin to address the potential role of lifestyle change on breast cancer outcomes.[8-11] These trials will directly address the contribution of dietary fat intake to breast cancer outcome; at least two of these studies will report on clinical end points this year. The WINS Study
The Women's Intervention Nutrition Study (WINS) has entered 2,400 women 48 years of age or older with early-stage, resected breast cancer. The women have been randomized to either control or dietary intervention groups, with the latter designed to result in dietary fat-intake reduction.[12] All hormone receptor-positive patients received tamoxifen; protocoldefined chemotherapy is required for receptor-negative patients, while chemotherapy is optional for those with receptor-positive disease. Counseling on weight loss is not an intervention target. Adherence to the intervention has been presented.[9] Clinical outcome results after about 5 years of median follow-up are anticipated for mid-2005. The major study end point, similar to adjuvant chemotherapy or hormonal therapy trials, is relapse-free survival including breast cancer recurrence and contralateral breast cancer development. The Women's Health Initiative Dietary Modification Trial
The dietary modification trial of the Women's Health Initiative is also a randomized, prospective multicenter clinical trial evaluating a lifestyle intervention vs a control condition.[ 11,13] The dietary intervention is a low-fat dietary pattern that is high in fruits, vegetables, and grains, hypothesized to reduce the risk of breast and colorectal cancer, and secondarily coronary heart disease, in otherwise healthy postmenopausal women. Accrual has been completed, with 48,836 postmenopausal women randomized and undergoing follow-up. Intermediate dietary adherence has been described.[14] By study design, outcomes will be evaluated and results presented following 8.5 years of follow-up later in 2005. The results from these two studies, separately evaluating the effect of dietary fat intake on breast cancer recurrence and breast cancer incidence, may provide the first definitive evidence sufficient to move lifestyle intervention strategies into active clinical practice.
The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.
1. Brown JK, Doyle C, Coumeya KS, et al: Nutrition and physical activity during and after cancer treatment: An American Cancer Society guide for informed choices. CA Cancer J Clin 53:268-291, 2003.
2. Cerhan JR, Potter JD, Gilmore JM, et al: Adherence to the AICR cancer prevention recommendations and subsequent morbidity and mortality in the Iowa Women's Health Study cohort. Cancer Epidemiol Biomarkers Prev 13:1114-1120, 2004.
3. Chlebowski R: The American Cancer Society Guide for Nutrition and Physical Activity for Cancer Survivors: A call to action for clinical investigators. Cancer J Clin 53:266-267, 2003.
4. Jain M, Miller AB, To T: Premorbid diet and the prognosis of women with breast cancer. J Natl Cancer Inst 86:1390-1397, 1994.
5. Zhang, Folsom AR, Sellers TA, et al: Better breast cancer survival for postmenopausal women who are less overweight and eat less fat: The Iowa Women's Health Study. Cancer 76:275-283, 1995.
6. Kroenke CH, Chen WY, Rosner B, et al: Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23:1370-1378, 2005.
7. Enger SM, Greif JM, Polikoff J, et al: Body weight correlates with mortality in early stage breast cancer. Arch Surg 139:954-960, 2004.
8. Boyd NF, Greenberg C, Lockwood G, et al: Effects of two years of a low-fat high-carbohydrate diet on radiologic features of the breast: Results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. J Natl Cancer Inst 89:488-496, 1997.
9. Chlebowski RT, Blackburn GL, Winters B, et al: Long term adherence to dietary fat reduction in the Women's Intervention Nutrition Study (WINS) (abstract 302). Proc Am Soc Clin Oncol 19:78a, 2000.
10. Pierce JP, Faerber S, Wright FA, et al, for the Women's Healthy Eating and Living (WHEL) study group: A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: The Women's Healthy Eating and Living (WHEL) study. Control Clin Trials 23:728-756, 2002.
11. Ritenbaugh C, Patterson RE, Chlebowski RT, et al: The Women's Health Initiative Dietary Modification trial: Overview and baseline characteristics of participants. Ann Epidemiol 13:S87-S97, 2003.
12. Chlebowski RT, Blackburn GL, Buzzard IM, et al: Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. J Clin Oncol 11:2072-2080, 1993.
13. Women's Health Initiative Study Group: Dietary adherence in the Women's Health Initiative Dietary Modification Trial. J Am Diet Assoc 104:654-658, 2004.
14. Patterson RE, Kristal A, Rodabough R, et al: Changes in food sources of dietary fat in response to an intensive low-fat dietary intervention: Early results from the Women's Health Initiative. J Am Diet Assoc 103:454-460, 2003.
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.